Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: Type II estrogen binding sites and tubulin

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 1861-1869

  Ter Haar, Ernst ^a,d   Hamel, Ernest ^c   Balachandran, Raghavan ^a   Day, Billy W ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Analog II; Breast cancer; Tubulin; Type II estrogen binding sites; Z chlorochalcone

Indexed keywords

1,1 DICHLORO 2,3 DIPHENYLCYCLOPROPANE; ANTINEOPLASTIC AGENT; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN RECEPTOR; TUBULIN;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; ESTROGEN BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANTINEOPLASTIC AGENTS; BINDING SITES; BINDING, COMPETITIVE; BREAST NEOPLASMS; CELL CYCLE; CHALCONE; CHALCONES; DIETHYLSTILBESTROL; ESTRADIOL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GUANOSINE TRIPHOSPHATE; HUMANS; MICROTUBULES; RECEPTORS, ESTROGEN; TAMOXIFEN; TUBULIN; TUMOR CELLS, CULTURED;

EID: 0030846513     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Magarian RA, Benjamin EJ: Syntheses of cyclopropyl analogs of stilbene and stilhenediol as possible antiestrogens. J Pharm Sci 64: 1626-1632, 1975.
2. Pento JT, Magarian RA, Wright RJ, King MM, Benjamin EJ: Non- steroidal estrogens and antiestrogen. Biological activity of cyclopropyl analogs of stilbene and stilbenediol. J Pharm Sci 70: 339-343, 1981.
3. Day BW, Magarian RA, Pento JT, Jain PT, Mousissian GK, Meyer KL: Synthesis and biological evaluation of 1,1-dichloro-2,2,3- triarylcyclopropanes as pure antiestrogens. J Med Chem 34: 842-851, 1991.
4. Pento JT, Magarian RA, King MM: A comparison of the efficacy for antitumor activity of the non-steroidal antiestrogens Analog II and tamoxifen in DMBA- induced rat mammary tumors. Cancer Lett 15: 261-269, 1982.
5. King MM, Pento JT, Magarian RA, Brueggemann GL: The interaction of dietary fat and antiestrogen treatment on DMBA- induced mammary tumors in the rat. Nutr Cancer 7: 239-249, 1985.
6. King MM, Magarian RA, Terao J, Brueggemann GL: Effects of nonsteroidal antiestrogens, Analog II and tamoxifen, on a metastatic transplantable rat mammary tumor. J Natl Cancer Inst 74: 447-451, 1985.
7. Ter Haar E, Day BW: Cytostatic and cytotoxic action of the antitumor agent Z-1,1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines. Anticancer Res 16: 1107-1115, 1996.
8. Martin MB, Saceda M, Garcia-Morales P, Gottardis MM: Regulation of estrogen receptor expression. Breast Cancer Res and Treatm 31: 183-189, 1994.
9. Erikkson H, Upchurch S, Hardin JW, Peck EJ, Clark JH: Heterogeneity of estrogen receptors in the cytosol and nuclear fractions of the rat uterus. Biochem Biophys Res Commun 81: 1-7, 1978.
10. Clark JH, Hardin JW, Upchurch S, Eriksson H: Heterogeneity of estrogen binding sites in the cytosol of the rat uterus. J Biol Chem 253: 7630-7634, 1978.
11. Syne JS, Markaverich BM, Clark JH, Panko WB: Estrogen binding sites in the nucleus of normal and malignant human tissue: characteristics of the multiple nuclear binding sites. Cancer Res 42: 4449-4454, 1982.
12. Scambia G, Raneletti FO, Benedetti Panici PB, Piantelli M, Bonanno G, De Vincenzo R, Ferandia G, Pierelli L, Capelli A, Manusco S: Quercetin inhibits the growth of a multidrug-resistant estrogen- receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen binding sites. Cancer Chemother Pharmacol 28: 255- 258, 1991.
13. Scambia G, Raneletti FO, Benedetti Panici P, Piantelli M, Rumi C, Battaglia F, Larocca LM, Capelli A, Mancuso S: Type-II estrogen binding sites in a lymphoblastoid cell line and growth inhibitory effect of estrogen, anti-estrogen and bioflavonoids. Int J Cancer 46: 1112- 1116, 1990.
14. Larocca LM, Piantelli M, Leone G, Sica S, Teofili L, Benedetti Panici, P, Scambia G, Mancuso S, Capelli A, Raneletti, FO: Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibtory effect of oestrogen and flavonoids, Br J Haematol 75: 489-495, 1990.
15. Scambia G, Raneletti FO, Benedetti Panici PB, Piantelli M, De Vincenzo R, Ferrandina G, Bonasso G, Capelli A, Mancuso S: Quercetin induces type-II estrogen-binding sites in estrogen-receptor- negative MDA-MB231. and estrogen-receptor-positive MCF-7 human breast-cancer cell lines. Int J Cancer 54: 462-466, 1993.
16. Markaverich BM, Gregory RR: Preliminary characterization and partial purification of rat uterine nuclear type II binding sites. Biochem Biophys Res Comm 177: 1283-1290, 1991.
17. Markaverich BM, Roberts RR, Alejandro MA, Johnson GA, Middleditch BS, Clark IH: Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J Steroid Biochem 30: 71-78, 1988.
18. Markaverich BM, Gregory RR. Preliminary assessment of luteolin as an affinity ligand for type II estrogen-binding sites in rat uterine nuclear extracts. Steroids 58: 268-274, 1993.
19. Markaverich BM, Schauweker TH, Gregory RR, Varma M, Kittrell FS, Medina D, Varma RS: Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bisbenzylidenecyclohexanones. Cancer Res 52: 2482-2488, 1992.
20. Markaverich BM, Schauweker TH, Gregory RR, Varma RS, Varma M, Kittrell FS, Medina D: Combination therapy with a nuclear type II site agonist and 5-fluorouracil: inhibition of mammary tumor growth, Int J Oncol 2: 385-392, 1993.
21. D'Amato RJ, Lin CM, Flynn E, FoLlcman J, Hamel E: 2- Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 91: 3964-3968, 1994.
22. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E: Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 38: 2041-2049, 1995.
23. Hamel E, Lin CM, Flynn E, D'Amato RJ: Interactions of 2- methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized tubulin and with tubulin polymers. Biochemistry 35: 1304-1310, 1996.
24. Sato Y, Sakakibara Y, Oda T, Aizu-Yokota E, Ichinoseki K: Effect of estradiol and ethynylestradiol on microtubule distribution in Chinese hamster V79 cells. Chem Pharm Bull 40: 182-184, 1992.
25. Aizu-Yokota E, Susaki A, Sato Y: Natural estrogens induce modulation of microtubules in Chinese hamster V79 cells in culture. Cancer Res 55: 1863-1868, 1995.
26. Kuijpers TW, Raleigh M, Kavanagh T, Janssen H, Calafat J, RODS D, Harlan JM: Cytokine-activated endothelial-cells internalize E-selectin into a lysosomal compartment of vesiculotubular shape - a tubulin- driven process. J Immunol 152: 5060-5069, 1994.
27. Byard EH, Lange BM: Tubulin and microtubules. Essays Biochem 26: 13-25, 1991.
28. Hamel E, Lin C: Separation of active tubulin and microtubule- associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. Biochemistry 23: 4173-4178, 1984.
29. Grover S, Rimoldi JM, Molinero AA, Chaudhary AG, Kingston DGI, Hamel E: Differential effects of paclitaxel (Taxol) analogs modified at positions C-2, C-7, and C-3′ on tubulin polymerization and polymer stabilization: identification of a hyperactive paclitaxel derivative. Biochemistry 34: 3927-3934, 1995.
30. Ter Haar E, Kowalski RJ, Hamel E, Lin CM, Longley RE, Gunasekera SP, Rosenkranz HS, Day BW: Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 35: 243-250, 1996.
31. Blokhin AV, Yoo H-D, Geralds RS, Nagle DE, Genvick WH, Hamel E: Characterization of the interaction of the marine cyanobacterial natural product curacin A with the colchicine site of tubulin and initial structure-activity studies with analogues. Mol Pharmacol 48: 523-531, 1995.
32. Bronzert DA, Greene GL, Lippman ME: Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 117: 1409-1417, 1985.
33. Thompson EW, Katz D, Shima TB, Wakeling AE, Lippman ME, Dickson RB: ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res 49: 6929-6934, 1985.
34. Engel, LW, Young NA: Human breast carcinoma cells in continuous culture: a review. Cancer Res 38: 4327-4339, 1978.
35. Cailleau R, Young R, Olive M, Reeves WJ Jr: Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53: 661-674, 1974.
36. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, Hamel E: Interactions of tubulin with potent natural and synthetic analogues of the antimitotic agent combretastatin, a structure-activity study. Mol Pharmacol 34: 200-208, 1988.
37. Cushman M, Nagarathnam D, Gopal D, Chakraborti AK, Lin CM, Hamel E: Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J Med Chem 34: 2579-2588, 1991.
38. Edwards ML, Stemerick DM, Sunkara PS: Chalcones: a new class of antimitotic agents. J Med Chem 33: 1948-1954, 1990.
39. Markaverich BM, Gregory RR, Alejandro MA, Kittrell FS, Medina D, Clark JH, Varma M, Varma RS: Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth. Cancer Res 50: 1470-1478, 1990.
40. Peyrot V, Leynadier D, Sarrazin M, Briand C, Rodriquez A, Meto JM, Andreu JM: Interaction of tubulin and cellular microtubules with the new antitumor drug MDL 27048: a powerful and reversible microtubule inhibitor. J Biol Chem 264: 21296-21301, 1989.